The agency first approved Victoza to treat patients with type 2 diabetes in 2010. The drug may now be used to reduce the risk of cardiovascular events — like heart attacks and strokes — in this patient population.
The expanded approval stems from a clinical trial, which showed Victoza reduced the risk of cardiovascular events by 13 percent compared to a placebo.
More articles on supply chain:
7 drugmakers in the headlines
Gilead to acquire Kite Pharma for nearly $12B: 4 things to know
Blood supplier expects shortages in Texas amid Hurricane Harvey
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
